• The 7 technologies described in this briefing are point-of-care (POC) creatinine tests used to measure kidney function before contrast-enhanced imaging.

  • The innovative aspects are that the tests give results from whole blood, blood plasma or blood serum samples in about 9 minutes or less. This helps to inform a decision on whether to proceed with contrast-enhanced imaging in people without a recent creatinine test result.

  • The intended place in therapy would be as an alternative to current laboratory-based creatinine testing in people needing contrast-enhanced imaging.

  • The key points from the evidence summarised in this briefing are from 7 observational studies with a total of 3,859 participants. Most of the included studies show that POC creatinine tests correlate very well with laboratory-based reference tests with acceptable specificity and sensitivity.

  • Key uncertainties around the evidence and technology are that there is no published evidence of effectiveness for several of the devices in this briefing and only 1 of the studies was conducted in the UK. Some of the devices included in the evidence were susceptible to variation in creatinine levels compared with laboratory reference tests. Specificity and sensitivity were not always reported and some devices included in this briefing are not represented in the evidence.

  • The cost of the products included in this briefing range from £4,995 to £35,000 (excluding VAT) without consumables. The resource impact would most likely be an increase in cost to the NHS, which could be offset by reduced incidences of cancelled scans and contrast-induced acute kidney injury (CI‑AKI).

This briefing describes technologies that fulfil a similar purpose. During development, every effort was made to identify and include relevant technologies but others may not have been identified, or key information was unavailable.